A prospective study on myocardial injury after BNT162b2 mRNA COVID-19 fourth dose vaccination in healthy persons

Nir Levi, Gil Moravsky, Tatyana Weitsman, Itshak Amsalem, Sarit Bar-Sheshet Itach, Nurit Algur, Ira Lapidus, Ofir Mitz, Michael Glikson, Yonit Wiener-Well, Tal Hasin, Nir Levi, Gil Moravsky, Tatyana Weitsman, Itshak Amsalem, Sarit Bar-Sheshet Itach, Nurit Algur, Ira Lapidus, Ofir Mitz, Michael Glikson, Yonit Wiener-Well, Tal Hasin

Abstract

Aims: To prospectively evaluate the incidence of myocardial injury after the administration of the fourth dose BNT162b2 mRNA vaccine (Pfizer-BioNTech) against COVID-19.

Methods and results: Health care workers who received the BNT162b2 vaccine during the fourth dose campaign had blood samples collected for high-sensitivity cardiac troponin (hs-cTn) during vaccine administration and 2-4 days afterward. Vaccine-related myocardial injury was defined as hs-cTn elevation above the 99th percentile upper reference limit and >50% increase from baseline measurement. Participants with evidence of myocardial injury underwent assessment for possible myocarditis. Of 324 participants, 192 (59.2%) were female and the mean age was 51.8 ± 15.0 years. Twenty-one (6.5%) participants had prior COVID-19 infection, the mean number of prior vaccine doses was 2.9 ± 0.4, and the median time from the last dose was 147 (142-157) days. Reported vaccine-related adverse reactions included local pain at injection site in 57 (17.59%), fatigue in 39 (12.04%), myalgia in 32 (9.88%), sore throat in 21 (6.48%), headache in 18 (5.5%), fever ≥38°C in 16 (4.94%), chest pain in 12 (3.7%), palpitations in 7 (2.16%), and shortness of breath in one (0.3%) participant. Vaccine-related myocardial injury was demonstrated in two (0.62%) participants, one had mild symptoms and one was asymptomatic; both had a normal electrocardiogram and echocardiography.

Conclusion: In a prospective investigation, an increase in serum troponin levels was documented among 0.62% of healthy health care workers receiving the fourth dose BNT162b2 vaccine. The two cases had mild or no symptoms and no clinical sequela.

Clinical trial registration: ClinicalTrials.gov Identifier: NCT05308680.

Keywords: COVID-19; Myocardial injury; Myocarditis; Vaccine; mRNA.

© 2022 European Society of Cardiology.

Figures

Figure 1
Figure 1
Changes in levels of high‐sensitivity cardiac troponin (hs‐cTn) in participants with vaccine‐related myocardial injury. *hs‐cTn I in participant no. 1 and hs‐cTn T in participant no. 2.

References

    1. Walsh EE, Frenck RW, Falsey AR, Kitchin N, Absalon J, Gurtman A, et al. Safety and immunogenicity of two RNA‐based Covid‐19 vaccine candidates. N Engl J Med. 2020;383:2439–50.
    1. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid‐19 vaccine. N Engl J Med. 2020;383:2603–15.
    1. Thomas SJ, Moreira ED, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid‐19 vaccine through 6 months. N Engl J Med. 2020;385:1761–73.
    1. Ryan M, Montgomery J, Engler R, Hoffman D, McClenathan B, Collins L, et al. Myocarditis following immunization with mRNA COVID‐19 vaccines in members of the US Military. JAMA Cardiol. 2021;6:1202–6.
    1. Marshall M, Ferguson ID, Lewis P, Jaggi P, Gagliardo C, Collins JS, et al. Symptomatic acute myocarditis in 7 adolescents after Pfizer‐BioNTech COVID‐19 vaccination. Pediatrics. 2021;148:e2021052478.
    1. Gargano JW, Wallace M, Hadler SC, Langley G, Su JR, Oster ME, et al. Use of mRNA COVID‐19 vaccine after reports of myocarditis among vaccine recipients: update from the Advisory Committee on Immunization Practices – United States, June 2021. MMWR Morb Mortal Wkly Rep. 2021;70:977–82.
    1. Barda N, Dagan N, Ben‐Shlomo Y, Kepten E, Waxman J, Ohana R, et al. Safety of the BNT162b2 mRNA Covid‐19 vaccine in a nationwide setting. N Engl J Med. 2020;385:1078–90.
    1. Mevorach D, Anis E, Cedar N, Bromberg M, Haas EJ, Nadir E, et al. Myocarditis after BNT162b2 mRNA vaccine against Covid‐19 in Israel. N Engl J Med. 2020;385:2140–9.
    1. Witberg G, Barda N, Hoss S, Richter I, Wiessman M, Aviv Y, et al. Myocarditis after Covid‐19 vaccination in a large health care organization. N Engl J Med. 2021;385:2132–9.
    1. Apple FS, Ler R, Murakami MAM. Determination of 19 cardiac troponin I and T assay 99th percentile values from a common presumably healthy population. Clin Chem. 2012;58:1574–81.
    1. Saenger AK, Beyrau R, Braun S, Cooray R, Dolci A, Freidank H, et al. Multicenter analytical evaluation of a high‐sensitivity troponin T assay. Clin Chim Acta. 2011;412:748–54.
    1. Sexson Tejtel SK, Munoz FM, Al‐Ammouri I, Savorgnan F, Guggilla RK, Khuri‐Bulos N, et al. Myocarditis and pericarditis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2022;40:1499–511.
    1. Caforio AL, Pankuweit S, Arbustini E, Basso C, Gimeno‐Blanes J, Felix SB, et al.; European Society of Cardiology Working Group on Myocardial and Pericardial Diseases . Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013;34:2636–48.
    1. Baden LR, el Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA‐1273 SARS‐CoV‐2 vaccine. N Engl J Med. 2021;384:403–16.
    1. Falsey AR, Sobieszczyk ME, Hirsch I, Sproule S, Robb ML, Corey L, et al. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV‐19) Covid‐19 vaccine. N Engl J Med. 2021;385:2348–60.
    1. Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P, et al. Vaccine side‐effects and SARS‐CoV‐2 infection after vaccination in users of the COVID symptom study app in the UK: a prospective observational study. Lancet Infect Dis. 2021;21:939–49.
    1. Regev‐Yochay G, Gonen T, Gilboa M, Mandelboim M, Indenbaum V, Amit S, et al. Efficacy of a fourth dose of Covid‐19 mRNA vaccine against Omicron. N Engl J Med. 2022;386:1377–80.
    1. Moreira ED, Kitchin N, Xu X, Dychter SS, Lockhart S, Gurtman A, et al.; C4591031 Clinical Trial Group . Safety and efficacy of a third dose of BNT162b2 Covid‐19 vaccine. N Engl J Med. 2022;386:1910–21.
    1. Oster ME, Shay DK, Su JR, Gee J, Creech CB, Broder KR, et al. Myocarditis cases reported after mRNA‐based COVID‐19 vaccination in the US from December 2020 to august 2021. JAMA. 2022;327:331–40.
    1. Shiyovich A, Witberg G, Aviv Y, Kornowski R, Hamdan A. A case series of myocarditis following third (booster) dose of COVID‐19 vaccination: magnetic resonance imaging study. Front Cardiovasc Med. 2022;9:839090.
    1. Mengesha B, Asenov AG, Hirsh‐Raccah B, Amir O, Pappo O, Asleh R. Severe acute myocarditis after the third (booster) dose of mRNA COVID‐19 vaccination. Vaccines (Basel). 2022;10:575.
    1. Caso F, Costa L, Ruscitti P, Navarini L, del Puente A, Giacomelli R, et al. Could Sars‐coronavirus‐2 trigger autoimmune and/or autoinflammatory mechanisms in genetically predisposed subjects? Autoimmun Rev. 2020;19:102524.
    1. Karikó K, Buckstein M, Ni H, Weissman D. Suppression of RNA recognition by toll‐like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity. 2005;23:165–75.
    1. Scharnhorst V, Krasznai K, van't Veer M, Michels RH. Variation of cardiac troponin I and T measured with sensitive assays in emergency department patients with noncardiac chest pain. Clin Chem. 2012;58:1208–14.
    1. Vasile VC, Saenger AK, Kroning JM, Klee GG, Jaffe AS. Biologic variation of a novel cardiac troponin I assay. Clin Chem. 2011;57:1080–1.
    1. Rittoo D, Jones A, Lecky B, Neithercut D. Elevation of cardiac troponin T, but not cardiac troponin I, in patients with neuromuscular diseases. J Am Coll Cardiol. 2014;63:2411–20.
    1. Punukollu G, Gowda RM, Khan IA, Mehta NJ, Navarro V, Vasavada BC, et al. Elevated serum cardiac troponin I in rhabdomyolysis. Int J Cardiol. 2004;96:35–40.
    1. Schmid J, Liesinger L, Birner‐Gruenberger R, Stojakovic T, Scharnagl H, Dieplinger B, et al. Elevated cardiac troponin T in patients with skeletal myopathies. J Am Coll Cardiol. 2018;71:1540–9.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться